These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1363127)

  • 1. [Changes in the renin-angiotensin system and the effectiveness of the treatment of hypertension with calcium antagonists, beta-adrenoblockers and diuretics].
    Svishchenko EP
    Kardiologiia; 1992 Sep; 32(9-10):41-4. PubMed ID: 1363127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
    Sim JJ; Bhandari SK; Shi J; Kalantar-Zadeh K; Rasgon SA; Sealey JE; Laragh JH
    Am J Hypertens; 2012 Mar; 25(3):379-88. PubMed ID: 22158065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in antihypertensive treatment--lessons from the National Acute Stroke Israeli (NASIS) registry.
    Koifman E; Tanne D; Molshatzki N; Leibowitz A; Grossman E
    Blood Press; 2014 Oct; 23(5):262-9. PubMed ID: 24483945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative analysis of the antihypertensive activity of calcium antagonists and adrenoblockers in long-term treatment].
    Svishchenko EP; Kupchinskaia EG; Zanozdra NS; Bezrodnaia LV; Radchenko VV
    Klin Med (Mosk); 1992; 70(11-12):34-7. PubMed ID: 1363481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of arterial hypertension. Clinical and pharmacological considerations].
    Silva Orrego P; Vera TV; Gual Julia JM; Gabbai F
    Arch Inst Cardiol Mex; 1987; 57(5):423-31. PubMed ID: 2892470
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and trends in the drug treatment of essential hypertension.
    van Zwieten PA
    J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pressor responses to antihypertensive drug types.
    Alderman MH; Cohen HW; Sealey JE; Laragh JH
    Am J Hypertens; 2010 Sep; 23(9):1031-7. PubMed ID: 20725055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hypertension with calcium antagonists.
    Murphy MB
    Int J Clin Pharmacol Res; 1985; 5(5):287-91. PubMed ID: 2866165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The place of the calcium antagonist verapamil in antihypertensive therapy.
    Bühler FR; Hulthén UL; Kiowski W; Müller FB; Bolli P
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S350-7. PubMed ID: 6184567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
    Andréjak M; Slama M; Hary L
    Therapie; 1998; 53(3):291-300. PubMed ID: 9773129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-entry blocking agents in the treatment of systemic hypertension.
    Robinson BF
    Am J Cardiol; 1985 Jan; 55(3):102B-106B. PubMed ID: 2857516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockers for management of hypertension.
    Catanzaro DF; Frishman WH
    South Med J; 2010 Jul; 103(7):669-73. PubMed ID: 20531060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone in the treatment of hypertension: a review.
    Brest AN
    Clin Ther; 1986; 8(5):568-85. PubMed ID: 2876776
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of essential hypertension].
    Koichev A
    Vutr Boles; 1985; 24(4):1-21. PubMed ID: 2866632
    [No Abstract]   [Full Text] [Related]  

  • 18. Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Sever PS; Chang CL; Prescott MF; Gupta A; Poulter NR; Whitehouse A; Scanlon M
    Eur Heart J; 2012 Dec; 33(23):2970-9. PubMed ID: 22942337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium antagonists, firstline partners for betablockers in hypertension.
    Bühler FR
    Z Kardiol; 1984; 73 Suppl 2():95-9. PubMed ID: 6152093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship of the renin-angiotensin-aldosterone system with auricular natriuretic factor in its response to the action of thiazide diuretics and to nifedipine, a sustained-release calcium antagonist].
    Ocón J; Mora-Macià J; Castellet R; del Río G
    Med Clin (Barc); 1994 Jan; 102(2):41-5. PubMed ID: 8133694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.